Literature DB >> 12526698

Radiochemical investigations of (99m)Tc-N(3)S-X-BBN[7-14]NH(2): an in vitro/in vivo structure-activity relationship study where X = 0-, 3-, 5-, 8-, and 11-carbon tethering moieties.

C Jeffrey Smith1, Hariprasad Gali, Gary L Sieckman, Chris Higginbotham, Wynn A Volkert, Timothy J Hoffman.   

Abstract

Bombesin (BBN), a 14 amino acid peptide, is an analogue of human gastrin releasing peptide (GRP) that binds to GRP receptors (GRPr) with high affinity and specificity. The GRPr is overexpressed on a variety of human cancer cells, including prostate, breast, lung, and pancreatic cancers. The specific aim of this study was to develop (99m)Tc-radiolabeled BBN analogues that maintain high specificity for the GRPr in vivo. A preselected synthetic sequence via solid-phase peptide synthesis (SPPS) was designed to produce N(3)S-BBN (N(3)S = dimethylglycyl-l-seryl-l-cysteinylglycinamide) conjugates with the following general structure: DMG-S-C-G-X-Q-W-A-V-G-H-L-M-(NH(2)), where the spacer group, X = 0 (no spacer), omega-NH(2)(CH(2))(2)COOH, omega-NH(2)(CH(2))(4)COOH, omega-NH(2)(CH(2))(7)COOH, or omega-NH(2)-(CH(2))(10)COOH. The new BBN constructs were purified by reversed phase-HPLC (RP-HPLC). Electrospray mass spectrometry (ES-MS) was used to characterize the nonmetalated BBN conjugates. Re(V)-BBN conjugates were prepared by the reaction of Re(V)gluconate with N(3)S-X-BBN[7-14]NH(2) (X = 0 carbons, beta-Ala (beta-alanine), 5-Ava (5-aminovaleric acid), 8-Aoc (8-aminooctanoic acid), and 11-Aun (11-aminoundecanoic acid)) with gentle heating. Re-N(3)S-5-Ava-BBN[7-14]NH(2) was also prepared by the reaction of [Re(V)dimethylglycyl-l-seryl-l-cysteinylglycinamide] with 5-Ava-BBN[7-14]NH(2). ES-MS was used to determine the molecular constitution of the new Re(V) conjugates. The (99m)Tc conjugates were prepared at the tracer level by each the prelabeling, post-conjugation and pre-conjugation, postlabeling approaches from the reaction of Na[(99m)TcO(4)] with excess SnCl(2), sodium gluconate, and corresponding ligand. The (99m)Tc and Re(V) conjugates behaved similarly under identical RP-HPLC conditions. In vitro and in vivo models demonstrated biological integrity of the new conjugates.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12526698     DOI: 10.1021/bc020034r

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  17 in total

1.  Synthesis and evaluation of novel Tc-99m labeled probestin conjugates for imaging APN/CD13 expression in vivo.

Authors:  Gopal Pathuri; Andria F Hedrick; Bryan C Disch; John T Doan; Michael A Ihnat; Vibhudutta Awasthi; Hariprasad Gali
Journal:  Bioconjug Chem       Date:  2011-12-20       Impact factor: 4.774

Review 2.  Bombesin receptor-mediated imaging and cytotoxicity: review and current status.

Authors:  Veronica Sancho; Alessia Di Florio; Terry W Moody; Robert T Jensen
Journal:  Curr Drug Deliv       Date:  2011-01       Impact factor: 2.565

3.  Metal-containing and related polymers for biomedical applications.

Authors:  Yi Yan; Jiuyang Zhang; Lixia Ren; Chuanbing Tang
Journal:  Chem Soc Rev       Date:  2016-02-24       Impact factor: 54.564

Review 4.  Radiolabeled bombesin derivatives for preclinical oncological imaging.

Authors:  Carolina de Aguiar Ferreira; Leonardo Lima Fuscaldi; Danyelle M Townsend; Domenico Rubello; André Luís Branco de Barros
Journal:  Biomed Pharmacother       Date:  2016-12-29       Impact factor: 6.529

Review 5.  Radiopharmaceutical development of radiolabelled peptides.

Authors:  Melpomeni Fani; Helmut R Maecke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

6.  Nuclear targeting with cell-specific multifunctional tricarbonyl M(I) (M is Re, (99m)Tc) complexes: synthesis, characterization, and cell studies.

Authors:  Teresa Esteves; Fernanda Marques; António Paulo; José Rino; Prasant Nanda; C Jeffrey Smith; Isabel Santos
Journal:  J Biol Inorg Chem       Date:  2011-06-25       Impact factor: 3.358

7.  In vitro structure-activity relationship of Re-cyclized octreotide analogues.

Authors:  Shorouk F Dannoon; Heather M Bigott-Hennkens; Lixin Ma; Fabio Gallazzi; Michael R Lewis; Silvia S Jurisson
Journal:  Nucl Med Biol       Date:  2010-07       Impact factor: 2.408

8.  Monooxorhenium(V) complexes with 222-N2S2 MAMA ligands for bifunctional chelator agents: Syntheses and preliminary in vivo evaluation.

Authors:  Dustin Wayne Demoin; Ashley N Dame; William D Minard; Fabio Gallazzi; Gary L Seickman; Tammy L Rold; Nicole Bernskoetter; Michael E Fassbender; Timothy J Hoffman; Carol A Deakyne; Silvia S Jurisson
Journal:  Nucl Med Biol       Date:  2016-08-31       Impact factor: 2.408

9.  [64Cu-NOTA-8-Aoc-BBN(7-14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues.

Authors:  Adam F Prasanphanich; Prasant K Nanda; Tammy L Rold; Lixin Ma; Michael R Lewis; Jered C Garrison; Timothy J Hoffman; Gary L Sieckman; Said D Figueroa; Charles J Smith
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-12       Impact factor: 11.205

10.  Isothiocyanate-Functionalized Bifunctional Chelates and fac-[M(I)(CO)3](+) (M = Re, (99m)Tc) Complexes for Targeting uPAR in Prostate Cancer.

Authors:  Benjamin B Kasten; Xiaowei Ma; Kai Cheng; Lihong Bu; Winston S Slocumb; Thomas R Hayes; Steven Trabue; Zhen Cheng; Paul D Benny
Journal:  Bioconjug Chem       Date:  2015-12-30       Impact factor: 4.774

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.